Skip to content

Study · In silico · 2021

1 result

Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.

Kanhed AM, Patel DV, Teli DM, Patel NR, Chhabria MT, Yadav MR

Molecular diversity31 Jul 2020Cited by 47 (Europe PMC)

PMID32737681 (opens in a new tab)PMCIDPMC7393348 (opens in a new tab)DOI10.1007/s11030-020-10130-1 (opens in a new tab)PepBankPUB-32737681
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoActivity measurement

    In a virtual screen of approved drugs against the SARS-CoV-2 main protease (Mpro), pralmorelin was identified as a predicted Mpro-binding hit.

    In plain wordsIn a computer screen, pralmorelin was picked as a possible hit against the main protease of the COVID-19 virus. No lab test was done.

    Peptide
    GHRP-2
    Outcome
    Not applicablePredicted Mpro inhibition by screening
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apart from these pralmorelin, iodixanol and iotrolan were also identified from the systematic screening.
    1 context sentence
    Summary · context
    A systematic screening of a drug library (having drugs and diagnostic agents which are approved by FDA or other world authorities) and the Asinex BioDesign library was carried out using pharmacophore and sequential conformational precision level filters using the Schrodinger Suite.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.